TABLE 4.

Mean hepatic WHV cccDNA contents prior to, during, and following the 10-week MIV-210 antiviral efficacy study

Time of liver biopsy	Placebo			MIV-210 treatment at:
				20 mg/kg/day			60 mg/kg/day
	No. of biopsy specimens	Mean log10 WHV cccDNA load (vge/μg)	Range of WHV cccDNA load (vge/μg)	No. of biopsy specimens	Mean log10 WHV cccDNA load (vge/μg)	Range of WHV cccDNA load (vge/μg)	No. of biopsy specimens	Mean log10 WHV cccDNA load (vge/μg)	Range of WHV cccDNA load (vge/μg)
Pretreatment	6	5.34	3.4 × 104-9.1 × 105	6	4.65	3.0 × 102a-5.8 × 105	6	5.25	7.0 × 104-3.1 × 105
After 10-wk treatment	6	5.38	8.4 × 104-7.4 × 105	6	2.82	0.6 × 101a-5.9 × 105	6	3.23	0.3 × 102b-7.4 × 104
After 10-wk follow-up	4	5.49	1.1 × 105-6.1 × 105	5	4.89	<1 × 102a-6.5 × 105	6	4.74	2.4 × 102b-0.2 × 105

^aValue from WM 3231, which cleared WHs antigenemia.

^bValue from WF 2433A, in which WHV viremia rapidly declined to <10² vge/ml after 2 weeks of treatment with MIV-210 at 60 mg/kg/day p.o. and the suppression was maintained at a comparably low level of viremia beyond the 10-week treatment period.